Gyre Therapeutics, Inc.
GYRE- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001124105
No open-market purchases or sales by Gyre Therapeutics, Inc. insiders were filed in the last 90 days; 59 institutions reported holding it in 13F filings for Q2 2026, worth $57.1M in total; no superinvestor holds it.
Open-market trades, last 90 days
Open-market purchases (P) and sales (S) by Gyre Therapeutics, Inc. insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.
- Open-market buys
- 0 filings
- Open-market sells
- 0 filings
- Insiders trading
- 0
- Net value
- $0
- Purchases minus sales
Insider roster
Directors, officers and 10% owners who have filed a Form 4 for Gyre Therapeutics, Inc., current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.
| Name | Title | Last reported holding | Last filing | Filings, past year |
|---|---|---|---|---|
| Weston Claire | Director | – | Aug 4, 2026 | 1 |
| Kirkby Maxwell | Director | – | Aug 4, 2026 | 1 |
| Epstein David M. | Director | – | Jun 30, 2026 | 1 |
| Carmichael Gordon | Director | – | Jun 30, 2026 | 1 |
| Parry Renate | Director | – | Jun 30, 2026 | 1 |
| Nussbaum Rodney L | Director | – | Jun 30, 2026 | 1 |
| Zhang Ping | Director | – | Jun 30, 2026 | 3 |
| Weng Dan | Director | – | Jun 30, 2026 | 1 |
| Ye Weiguo | Chief Operating Officer | 700,000 | Jun 22, 2026 | 8 |
| Luo Ying | Chief Executive Officer | 2,565,226Indirect | Jun 10, 2026 | 2 |
| Bergmann Joshua Benjamin | GC and Corporate Secretary | – | Jun 10, 2026 | 1 |
| GNI Group Ltd. | 10% Owner | 64,005,887Indirect | May 6, 2026 | 1 |
| GNI USA, Inc. | 10% Owner | 64,005,887Indirect | May 6, 2026 | 1 |
| Eastling Thomas Wilson | Chief Financial Officer | 15,000 | May 6, 2026 | 1 |
| Chen Ruoyu | Chief Financial Officer | – | Jan 9, 2026 | 1 |
| Ma Songjiang | President | 2,806,084Indirect | May 29, 2025 | 0 |
| Ying Han | Chief Executive Officer | – | Aug 16, 2024 | 0 |
| Usman Nassim | Director | 1,636 | Jul 1, 2024 | 0 |
| Wu Charles C | Chief Executive Officer | – | Nov 22, 2023 | 0 |
| GNI Hong Kong Ltd | 10% Owner | 0 | Oct 27, 2023 | 0 |
| Lawlor Augustine | Director | 0Indirect | Sep 1, 2023 | 0 |
| Hunt Andrea | Director | 0 | Sep 1, 2023 | 0 |
| Miller Seline E. | SVP Finance; Interim CFO & PAO | 0 | Sep 1, 2023 | 0 |
| Blouse Grant E. | Chief Scientific Officer | 9,417 | Aug 10, 2022 | 0 |
| Williams Eddie | Director | 34,804 | Jan 7, 2022 | 0 |
| Ling Geoffrey M.D. | Director | 31,790 | Jan 7, 2022 | 0 |
| Desouza Errol B | Director | 29,801 | Oct 5, 2021 | 0 |
| Jew Jeanne Y | Director | – | Sep 13, 2021 | 0 |
| Levy Howard | Chief Medical Officer | 639 | Aug 11, 2021 | 0 |
| Tetlow Sharon | Director | – | Jul 2, 2021 | 0 |
Insider trades
Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| May 20, 2025 (view filing) | May 16-19 | 4 days | Ma SongjiangPresident | SSale | −4.00K | $11.21 | −$44.8K | −0.1%2.81M after | 2 lots10b5-1 |
| May 22, 2025 (view filing) | May 20-21 | 2 days | Ma SongjiangPresident | SSale | −4.00K | $11.04 | −$44.2K | −0.1%2.81M after | 2 lots10b5-1 |
| May 27, 2025 (view filing) | May 22-23 | 5 days | Ma SongjiangPresident | SSale | −2.18K | $10.91 | −$23.8K | −0.1%2.81M after | 2 lots10b5-1 |
| May 29, 2025 (view filing) | May 27-28 | 2 days | Ma SongjiangPresident | SSale | −2.56K | $10.23 | −$26.2K | −0.1%2.81M after | 2 lots10b5-1 |
| May 7, 2026 (view filing) | May 5-6 | 2 days | Luo YingChief Executive Officer | SSale | −10.3K | $8.04 | −$82.9K | −0.4%2.57M after | 2 lots10b5-1 |
| May 18, 2026 (view filing) | May 14-15 | 4 days | Ye WeiguoChief Operating Officer | SSale | −28.7K | $6.79 | −$194.8K | −3.9%700.0K after | 2 lots |
| May 20, 2026 (view filing) | May 18-19 | 2 days | Ye WeiguoChief Operating Officer | SSale | −9.32K | $6.38 | −$59.4K | −1.3%700.0K after | 2 lots |
| May 22, 2026 (view filing) | May 20-21 | 2 days | Ye WeiguoChief Operating Officer | SSale | −22.2K | $6.15 | −$136.7K | −3.1%700.0K after | 2 lots |
| May 27, 2026 (view filing) | May 22-26 | 5 days | Ye WeiguoChief Operating Officer | SSale | −7.50K | $6.09 | −$45.7K | −1.1%700.0K after | 2 lots |
| Jun 8, 2026 (view filing) | Jun 4-5 | 4 days | Ye WeiguoChief Operating Officer | SSale | −35.0K | $6.25 | −$218.6K | −4.8%700.0K after | 2 lots |
| Jun 11, 2026 (view filing) | Jun 9-10 | 2 days | Ye WeiguoChief Operating Officer | SSale | −20.9K | $6.16 | −$128.9K | −2.9%700.0K after | 2 lots |
| Jun 15, 2026 (view filing) | Jun 11 | 4 days | Ye WeiguoChief Operating Officer | SSale | −2.80K | $6.17 | −$17.3K | −0.4%700.0K after | |
| Jun 22, 2026 (view filing) | Jun 9-18 | 13 daysLate | Ye WeiguoChief Operating Officer | SSale | −11.0K | $6.25 | −$68.7K | −1.5%700.0K after | 3 lots |